Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018119418 - METHODS RELATING TO THE TREATMENT OF CHEMORESISTANT AND IMMUNO-RESISTANT CANCER

Publication Number WO/2018/119418
Publication Date 28.06.2018
International Application No. PCT/US2017/068251
International Filing Date 22.12.2017
IPC
A61K 31/7105 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
Applicants
  • NIVIEN THERAPEUTICS COMPANY [US]/[US]
Inventors
  • SHAH, Nikita
  • HORWITZ, Nathaniel
Agents
  • RUSSELL, Hathaway, P.
  • AKHIEZER, Alexander
  • BROW, William, E.
  • BLOUNT, Jennifer, V.
  • ABELLEIRA, Susan, M.
Priority Data
62/439,02224.12.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS RELATING TO THE TREATMENT OF CHEMORESISTANT AND IMMUNO-RESISTANT CANCER
(FR) PROCÉDÉS ASSOCIÉS AU TRAITEMENT DU CANCER CHIMIO-RÉSISTANT ET IMMUNO-RÉSISTANT
Abstract
(EN)
Disclosed herein are methods of treating, reducing, delaying, preventing or inhibiting the proliferation, growth, and/or migration of cancer, such as those that are chemoresistant or immune-resistant, or both. Such methods comprise administering an inhibitor of, or disrupting, components that activate the Hippo- Yap pathway, such as through phosphorylation of YAP, including MST1/2, LATS1/2, NF2, MAP4Ks, TAOK1/3, in combination with therapeutic agents, such as chemotherapy, chemotherapeutic agent, anticancer agent, antineoplastic agent, cytotoxic agent, anti-angiogenesis agent, and immune checkpoint inhibitor, or combinations thereof.
(FR)
L'invention concerne des procédés de traitement, de réduction, de retardement, de prévention ou d'inhibition de la prolifération, de la croissance et/ou de la migration du cancer, tels que ceux qui sont chimio-résistants ou immuno-résistants, ou les deux. De tels procédés comprennent l'administration d'un inhibiteur de, ou de perturbation, des composants qui activent la voie de signalisation Hippo-yap, par exemple par phosphorylation de YAP, comprenant MST1/2, LATS1/2, NF2, MAP4Ks, TAOK1/3, en combinaison avec des agents thérapeutiques, tels qu'une chimiothérapie, un agent chimiothérapeutique, un agent anticancéreux, un agent antinéoplasique, un agent cytotoxique, un agent anti-angiogenèse, et un inhibiteur de point de contrôle immunitaire, ou des combinaisons de ceux-ci.
Latest bibliographic data on file with the International Bureau